Stephanie Curry, MD
Endocrinology, Diabetes & Metabolism · Johnston, RINPI 1508152778
Payments from drug & device makers
Across 410 payments — averaging $19.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- AbbVie$982
- Sanofi-aventis U.S. LLC$603
- Boehringer Ingelheim$549
- Johnson & Johnson$467
- plus $3K from 37 others
What the payments were for
- Food & beverage$7,868100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$111
- INVOKANA$109
- SOLIQUA 100/33$107
- TOUJEO$107
How this compares
$7,874 in reported general payments places this provider in the 70th percentile of 30 endocrinology, diabetes & metabolism providers in Rhode Island.
See all endocrinology, diabetes & metabolism providers in Rhode Island →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 549 | $628,587 |
| JardianceEmpagliflozin | 377 | $319,959 |
| TrulicityDulaglutide | 268 | $272,907 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 178 | $217,491 |
| MounjaroTirzepatide | 180 | $199,011 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 174 | $133,932 |
| RybelsusSemaglutide | 68 | $70,711 |
| JanuviaSitagliptin Phosphate | 84 | $69,422 |
| Lyumjev Kwikpen U-200Insulin Lispro-Aabc | 38 | $64,824 |
| Tresiba Flextouch U-200Insulin Degludec | 68 | $63,375 |
| FarxigaDapagliflozin Propanediol | 70 | $51,749 |
| Tresiba Flextouch U-100Insulin Degludec | 68 | $41,018 |
| ProliaDenosumab | 21 | $36,723 |
| Cinacalcet Hcl | 49 | $33,690 |
| Humalog Kwikpen U-100Insulin Lispro | 143 | $33,308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,571 | $699,298617 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Lyumjev | $1,053 | $487,468473 claims |
| Boehringer IngelheimJardiance | $549 | $319,959377 claims |
| MerckJanuvia | $154 | $69,42284 claims |
| AstraZenecaFarxiga | $264 | $51,74970 claims |
| AmgenProlia | $102 | $36,72321 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $603 | $16,71117 claims |
| IBSA Pharma Inc.Tirosint | $57 | $15,751104 claims |
| AbbVieSynthroid | $982 | $12,447108 claims |
| Antares Pharma, Inc.Xyosted | $23 | $6,97912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 30 endocrinology, diabetes & metabolism providers in Rhode Island.
Other endocrinology, diabetes & metabolism in Johnston
- Sudhir BansalWarwick$2.4M
- Robert DobrzynskiProvidence$245K
- Frank D'alessandroNorth Providence$193K
- Ricardo Correa MarquezEast Providence$94K
- Robert SmithProvidence$80K
- Joseph TucciProvidence$30K
- Amanda FernandesRiverside$28K
- Judith GilmoreWakefield$11K
- Beatriz DemoranvilleWarwick$5K
- Raquel CarneiroRiverside$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.